Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Strattera

- PMLiVE

ADA: Lilly’s once-weekly diabetes drug bests Januvia and Byetta

Late-stage trials of dulaglutide show superiority over established brands

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

- PMLiVE

Boehringer/ Lilly launch online diabetes management game

Pharma companies aim to raise awareness of type 2 diabetes complications

- PMLiVE

Another setback for Lilly as lymphoma drug fails

Late-stage candidate enzastaurin shows disappointing phase III results

- PMLiVE

Lilly expects to submit five drugs for US approval in 2013

Hopes FDA submissions will help offset patent losses for Zyprexa and Cymbalta

Lilly ramps up social media use

Next phase of LillyPad blog expansion aims at journalists

- PMLiVE

Medical researcher jailed for faking trial data

MHRA completes first prosecution under Good Laboratory Practice Regulations

- PMLiVE

Lilly “plans to axe a third of US sales reps”

Cuts come ahead of key patent expiries for Cymbalta and Evista

- PMLiVE

Lilly to invest extra $180m in US insulin manufacturing

Response to growing demand for insulin pens for people with diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links